RUX-based combination trials currently under investigation in MF
| Class . | Agent (combined with RUX) . | Target(s) . | Phase . | Status . | ClinicalTrials.gov identifier . |
|---|---|---|---|---|---|
| Epigenetic agents | Azacitidine | DNA methylation | 2 | Recruiting | NCT01787487 |
| Decitabine | DNA methylation | 1/2 | Ongoing, not recruiting | NCT02076191 | |
| Pracinostat | HDAC | 2 | Ongoing, not recruiting | NCT02267278 | |
| Panobinostat | HDAC | 1 | Ongoing, not recruiting | NCT01433445 | |
| Panobinostat | HDAC | 1/2 | Ongoing, not recruiting | NCT01693601 | |
| Hedgehog pathway inhibitors | Sonidegib | SMO | 1/2 | Ongoing, not recruiting | NCT01787552 |
| JAKis | Itacitinib | JAK1 | 2 | Recruiting | NCT03144687 |
| Immunomodulators | Thalidomide | Immunomodulation | 2 | Recruiting | NCT03069326 |
| Lenalidomide | Immunomodulation | 2 | Ongoing, not recruiting | NCT01375140 | |
| Pomalidomide | Immunomodulation | 1/2 | Recruiting | NCT01644110 | |
| PI3K/AKT/mTOR pathway inhibitors | INCB050465 | PI3K-δ | 2 | Recruiting | NCT02718300 |
| TGR-1202 | PI3K-δ | 1 | Recruiting | NCT02493530 | |
| Other agents | Ribociclib/PIM447 | CDK4/6 inhibitor Pan-PIM kinases | 1 | Ongoing, not recruiting | NCT02370706 |
| PU-H71 | HSP90 | 1 | Recruiting | NCT03373877 | |
| Pevonedistat | NAE | 1 | Not yet recruiting | NCT03386214 | |
| Sotatercept | ActRIIA ligands | 2 | Recruiting | NCT01712308 | |
| Luspatercept | ActRIIB ligands | 2 | Recruiting | NCT03194542 | |
| Peg-IFN α-2a | 1/2 | Recruiting | NCT02742324 |
| Class . | Agent (combined with RUX) . | Target(s) . | Phase . | Status . | ClinicalTrials.gov identifier . |
|---|---|---|---|---|---|
| Epigenetic agents | Azacitidine | DNA methylation | 2 | Recruiting | NCT01787487 |
| Decitabine | DNA methylation | 1/2 | Ongoing, not recruiting | NCT02076191 | |
| Pracinostat | HDAC | 2 | Ongoing, not recruiting | NCT02267278 | |
| Panobinostat | HDAC | 1 | Ongoing, not recruiting | NCT01433445 | |
| Panobinostat | HDAC | 1/2 | Ongoing, not recruiting | NCT01693601 | |
| Hedgehog pathway inhibitors | Sonidegib | SMO | 1/2 | Ongoing, not recruiting | NCT01787552 |
| JAKis | Itacitinib | JAK1 | 2 | Recruiting | NCT03144687 |
| Immunomodulators | Thalidomide | Immunomodulation | 2 | Recruiting | NCT03069326 |
| Lenalidomide | Immunomodulation | 2 | Ongoing, not recruiting | NCT01375140 | |
| Pomalidomide | Immunomodulation | 1/2 | Recruiting | NCT01644110 | |
| PI3K/AKT/mTOR pathway inhibitors | INCB050465 | PI3K-δ | 2 | Recruiting | NCT02718300 |
| TGR-1202 | PI3K-δ | 1 | Recruiting | NCT02493530 | |
| Other agents | Ribociclib/PIM447 | CDK4/6 inhibitor Pan-PIM kinases | 1 | Ongoing, not recruiting | NCT02370706 |
| PU-H71 | HSP90 | 1 | Recruiting | NCT03373877 | |
| Pevonedistat | NAE | 1 | Not yet recruiting | NCT03386214 | |
| Sotatercept | ActRIIA ligands | 2 | Recruiting | NCT01712308 | |
| Luspatercept | ActRIIB ligands | 2 | Recruiting | NCT03194542 | |
| Peg-IFN α-2a | 1/2 | Recruiting | NCT02742324 |
ActR, activin receptor; HDAC, histone deacetylase; HSP90, heat-shock protein 90; IFN, interferon; NAE, NEDD8-activating enzyme; Peg-IFN α-2a, Peg-interferon alpha-2a.